<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1349-7006</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Cancer Science</journal-title></journal-title-group><issn pub-type="ppub">1347-9032</issn><issn pub-type="epub">1349-7006</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28267243</article-id><article-id pub-id-type="pmc">5480076</article-id><article-id pub-id-type="doi">10.1111/cas.13232</article-id><article-id pub-id-type="publisher-id">CAS13232</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Overall survival of first&#x02010;line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study</article-title><alt-title alt-title-type="left-running-head">Oya <italic>et&#x000a0;al</italic>.</alt-title></title-group><contrib-group><contrib id="cas13232-cr-0001" contrib-type="author" corresp="yes"><name><surname>Oya</surname><given-names>Mototsugu</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2048-4263</contrib-id><address><email>moto-oya@z3.keio.jp</email></address><xref ref-type="aff" rid="cas13232-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cas13232-cr-0002" contrib-type="author"><name><surname>Tomita</surname><given-names>Yoshihiko</given-names></name><xref ref-type="aff" rid="cas13232-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="cas13232-curr-0001">
<sup>10</sup>
</xref></contrib><contrib id="cas13232-cr-0003" contrib-type="author"><name><surname>Fukasawa</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="cas13232-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="cas13232-cr-0004" contrib-type="author"><name><surname>Shinohara</surname><given-names>Nobuo</given-names></name><xref ref-type="aff" rid="cas13232-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="cas13232-cr-0005" contrib-type="author"><name><surname>Habuchi</surname><given-names>Tomonori</given-names></name><xref ref-type="aff" rid="cas13232-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="cas13232-cr-0006" contrib-type="author"><name><surname>Rini</surname><given-names>Brian I.</given-names></name><xref ref-type="aff" rid="cas13232-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="cas13232-cr-0007" contrib-type="author"><name><surname>Fujii</surname><given-names>Yosuke</given-names></name><xref ref-type="aff" rid="cas13232-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="cas13232-cr-0008" contrib-type="author"><name><surname>Kamei</surname><given-names>Yoichi</given-names></name><xref ref-type="aff" rid="cas13232-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="cas13232-cr-0009" contrib-type="author"><name><surname>Umeyama</surname><given-names>Yoshiko</given-names></name><xref ref-type="aff" rid="cas13232-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="cas13232-cr-0010" contrib-type="author"><name><surname>Bair</surname><given-names>Angel H.</given-names></name><xref ref-type="aff" rid="cas13232-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="cas13232-cr-0011" contrib-type="author"><name><surname>Uemura</surname><given-names>Hirotsugu</given-names></name><xref ref-type="aff" rid="cas13232-aff-0009">
<sup>9</sup>
</xref></contrib></contrib-group><aff id="cas13232-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Urology</named-content><institution>Keio University School of Medicine</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><aff id="cas13232-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Urology</named-content><institution>Yamagata University Faculty of Medicine</institution><named-content content-type="city">Yamagata</named-content><country country="JP">Japan</country></aff><aff id="cas13232-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Prostate Center and Division of Urology</named-content><institution>Chiba Cancer Center</institution><named-content content-type="city">Chiba</named-content><country country="JP">Japan</country></aff><aff id="cas13232-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Urology</named-content><institution>Hokkaido University Graduate School of Medicine</institution><named-content content-type="city">Hokkaido</named-content><country country="JP">Japan</country></aff><aff id="cas13232-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Urology</named-content><institution>Akita University School of Medicine</institution><named-content content-type="city">Akita</named-content><country country="JP">Japan</country></aff><aff id="cas13232-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Department of Solid Tumor Oncology</named-content><institution>Cleveland Clinic</institution><institution>Taussig Cancer Institute</institution><named-content content-type="city">Cleveland</named-content><named-content content-type="country-part">Ohio</named-content><country country="US">USA</country></aff><aff id="cas13232-aff-0007"><label><sup>7</sup></label><institution>Pfizer Japan</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><aff id="cas13232-aff-0008"><label><sup>8</sup></label><institution>Pfizer Oncology</institution><named-content content-type="city">San Diego</named-content><named-content content-type="country-part">California</named-content><country country="US">USA</country></aff><aff id="cas13232-aff-0009"><label><sup>9</sup></label><named-content content-type="organisation-division">Department of Urology</named-content><institution>Kindai University Faculty of Medicine</institution><named-content content-type="city">Osaka</named-content><country country="JP">Japan</country></aff><aff id="cas13232-curr-0001"><label><sup>10</sup></label>Present address: <institution>Niigata University Graduate School of Medical and Dental Sciences</institution><named-content content-type="city">Niigata</named-content><country country="JP">Japan</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Mototsugu Oya, Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku&#x02010;ku, Tokyo 160&#x02010;8582, Japan. Tel: +81 3 5363 3824; Fax: +81 3 3225 1985;<break/>
E&#x02010;mail: <email>moto-oya@z3.keio.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2017</year></pub-date><volume>108</volume><issue>6</issue><issue-id pub-id-type="doi">10.1111/cas.2017.108.issue-6</issue-id><fpage>1231</fpage><lpage>1239</lpage><history><date date-type="received"><day>12</day><month>12</month><year>2016</year></date><date date-type="rev-recd"><day>27</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>02</day><month>3</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 Japanese Cancer Association <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Cancer Science</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japanese Cancer Association.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAS-108-1231.pdf"/><abstract id="cas13232-abs-0001"><p>Subgroup analyses of a randomized global phase II study of axitinib showed objective response rate of 66% and median progression&#x02010;free survival of 27.6&#x000a0;months in treatment&#x02010;na&#x000ef;ve Japanese patients with metastatic renal cell carcinoma (<styled-content style="fixed-case">RCC</styled-content>). This analysis evaluated overall survival (<styled-content style="fixed-case">OS</styled-content>) and safety in 44 Japanese patients and compared the results with 169 non&#x02010;Japanese patients. In addition, baseline characteristics for predictive factors that may influence <styled-content style="fixed-case">OS</styled-content> in first&#x02010;line metastatic <styled-content style="fixed-case">RCC</styled-content> were explored in all patients using a Cox proportional hazard model. With median follow&#x02010;up of 33&#x000a0;months, fewer than half (16 of 44) of the Japanese patients had died and median <styled-content style="fixed-case">OS</styled-content> was not reached (95% confidence interval [<styled-content style="fixed-case">CI</styled-content>], 38.8&#x000a0;months&#x02013;not estimable), whereas 107 of 169 (63%) non&#x02010;Japanese patients had died and median <styled-content style="fixed-case">OS</styled-content> was 33.9&#x000a0;months (95% <styled-content style="fixed-case">CI</styled-content>, 28.9&#x02013;42.7). Estimated 1&#x02010;year, 2&#x02010;year and 3&#x02010;year survival probability (95% <styled-content style="fixed-case">CI</styled-content>) was 86.4% (76.2&#x02013;96.5), 75.0% (62.2&#x02013;87.8) and 68.2% (54.4&#x02013;81.9), respectively, in Japanese patients, and was higher than that in non&#x02010;Japanese patients (75.1% [68.4&#x02013;81.8], 62.1% [54.5&#x02013;69.7] and 47.2% [39.3&#x02013;55.1], respectively). The updated safety analysis did not reveal any new adverse events of concern among Japanese or non&#x02010;Japanese patients. The multivariate analysis identified that lower baseline Eastern Cooperative Oncology Group performance status, lower baseline tumor burden, and longer time from histopathological diagnosis to treatment were significant positive predictors of <styled-content style="fixed-case">OS</styled-content>. The current analysis confirmed the clinical activity of axitinib in treatment&#x02010;na&#x000ef;ve Japanese patients with metastatic <styled-content style="fixed-case">RCC</styled-content>, with an acceptable toxicity profile.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cas13232-kwd-0001">Antiangiogenic agent</kwd><kwd id="cas13232-kwd-0002">axitinib</kwd><kwd id="cas13232-kwd-0003">clinical trial phase <styled-content style="fixed-case">II</styled-content></kwd><kwd id="cas13232-kwd-0004">Japanese</kwd><kwd id="cas13232-kwd-0005">renal cell carcinoma</kwd></kwd-group><funding-group><award-group><funding-source>Pfizer</funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="6"/><page-count count="9"/><word-count count="7743"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>cas13232</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.1 mode:remove_FC converted:22.06.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cas13178-cit-1001">
<source>Cancer Sci</source>
<volume>108</volume> (<year>2017</year>) <fpage>1231</fpage>&#x02013;<lpage>1239</lpage>
</mixed-citation>
</p></notes><notes><fn-group id="cas13232-ntgp-0001"><fn id="cas13232-note-1001"><p>This trial is registered at ClinicalTrials.gov, NCT00835978.</p></fn><fn fn-type="funding" id="cas13232-note-1002"><p>
<bold>Funding Information</bold>
</p><p>This study was sponsored by Pfizer.</p></fn></fn-group></notes></front><body><p>Over the past decade, the landscape of treatment options for advanced and metastatic renal cell carcinoma (RCC) has evolved significantly with the approval of several targeted agents, including vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (TKI), anti&#x02010;VEGF monoclonal antibody, mammalian target of rapamycin inhibitors, and anti&#x02010;programmed death 1 monoclonal antibody. Axitinib, a potent and selective inhibitor of VEGF receptors 1&#x02013;3, was approved in 2012 for the treatment of advanced RCC after failure of one prior therapy, based on a significantly longer progression&#x02010;free survival (PFS) compared with sorafenib in a head&#x02010;to&#x02010;head randomized phase III Axitinib Second&#x02010;line (AXIS) trial.<xref rid="cas13232-bib-0001" ref-type="ref">1</xref> Although an improved PFS with axitinib treatment remained in the follow&#x02010;up analysis, it did not translate to a longer survival benefit.<xref rid="cas13232-bib-0002" ref-type="ref">2</xref>
</p><p>In treatment&#x02010;na&#x000ef;ve patients with metastatic RCC in a randomized open&#x02010;label phase&#x000a0;III trial, the difference in median PFS between axitinib and sorafenib did not reach significance<xref rid="cas13232-bib-0003" ref-type="ref">3</xref> and no survival advantage was observed with axitinib over sorafenib.<xref rid="cas13232-bib-0004" ref-type="ref">4</xref> However, axitinib showed antitumor activity with an acceptable safety profile. The National Comprehensive Cancer Network now includes axitinib among the first&#x02010;line treatment options for metastatic unresectable RCC, in addition to its well&#x02010;established position in the second&#x02010;line setting.<xref rid="cas13232-bib-0005" ref-type="ref">5</xref>
</p><p>Antitumor activity and the safety of axitinib for metastatic RCC in the first&#x02010;line setting was also investigated in a multinational, randomized phase II trial, in which the effect of axitinib dose titration on efficacy and safety was evaluated prospectively.<xref rid="cas13232-bib-0006" ref-type="ref">6</xref> The study showed that a statistically higher proportion of patients in the axitinib dose&#x02010;titration group achieved an objective response compared with the placebo dose&#x02010;titration group, providing evidence for the clinical benefit of individualized dose titration in some patients. Furthermore, median overall survival (OS) was found to be numerically longer in patients who received axitinib dose titration compared with those who received placebo dose titration.<xref rid="cas13232-bib-0007" ref-type="ref">7</xref>
</p><p>Although the efficacy and safety of axitinib have previously been shown in Japanese patients with metastatic RCC in the second&#x02010;line setting on the basis of a Japanese phase II study<xref rid="cas13232-bib-0008" ref-type="ref">8</xref>, <xref rid="cas13232-bib-0009" ref-type="ref">9</xref> and a subgroup analysis of the AXIS trial,<xref rid="cas13232-bib-0010" ref-type="ref">10</xref> there has been no such report for the first&#x02010;line setting. To investigate whether axitinib is efficacious and safe in Japanese patients with metastatic RCC in the first&#x02010;line setting and, if so, whether Japanese patients achieve better efficacy outcomes than non&#x02010;Japanese patients, we conducted a subgroup analysis from this multinational, randomized phase II trial. The analysis indicated that axitinib is effective, with median PFS exceeding 2&#x000a0;years, and is well tolerated in treatment&#x02010;na&#x000ef;ve Japanese patients with metastatic RCC.<xref rid="cas13232-bib-0011" ref-type="ref">11</xref> The objective response rate (95% CI) in Japanese patients was 66% (50&#x02013;80) compared with 44% (36&#x02013;52) in non&#x02010;Japanese patients, providing further evidence for more favorable clinical outcomes in axitinib&#x02010;treated Japanese patients. The aim of the current analysis was to evaluate the OS and the safety of treatment with first&#x02010;line axitinib in Japanese patients with metastatic RCC in this phase&#x000a0;II study. In addition, we investigated potential predictive values of baseline characteristics for OS using the data from all patients enrolled in this study.</p><sec id="cas13232-sec-0002"><title>Patients and Methods</title><sec id="cas13232-sec-0003"><title>Study design, patients and treatment</title><p>The study design and patient eligibility criteria have been described in detail elsewhere.<xref rid="cas13232-bib-0006" ref-type="ref">6</xref>, <xref rid="cas13232-bib-0011" ref-type="ref">11</xref> In brief, patients aged &#x02265;18&#x000a0;years with histologically confirmed metastatic RCC with a component of clear cell histology were enrolled from six countries, including Japan, in this multicenter, double&#x02010;blind, randomized phase II study.</p><p>All patients received axitinib 5&#x000a0;mg b.i.d. during a 4&#x02010;week lead&#x02010;in period. Patients who met the randomization criteria at the end of the lead&#x02010;in period were stratified by Eastern Cooperative Oncology Group performance status (ECOG PS) and randomly assigned (1:1) to axitinib with or without titration. The randomization criteria were: blood pressure &#x02264;150/90&#x000a0;mm Hg, absence of drug&#x02010;related grade 3 or 4 adverse events (AE) according to the NCI Common Terminology Criteria for Adverse Events (NCI&#x02010;CTCAE) v3.0, no axitinib dose reductions, and use of no more than two concurrent antihypertensive medications for 2 consecutive weeks. Patients who did not meet the randomization criteria continued on axitinib in a non&#x02010;randomized arm.</p><p>Following the lead&#x02010;in period, patients in the axitinib&#x02010;titration or placebo&#x02010;titration arm had their daily dose titrated to 7&#x000a0;mg b.i.d. (i.e. 5&#x000a0;mg axitinib plus either 2&#x000a0;mg axitinib or placebo). If patients tolerated the 7&#x000a0;mg b.i.d. dose by meeting the dose titration (i.e. randomization) criteria for 2 consecutive weeks, the dose could then be increased to a maximum of 10&#x000a0;mg b.i.d. (i.e. 5&#x000a0;mg axitinib plus either 5&#x000a0;mg axitinib or placebo). The axitinib dose could also be reduced from 5&#x000a0;mg b.i.d. to 3&#x000a0;mg b.i.d., and then to 2&#x000a0;mg b.i.d., if necessary, to manage axitinib&#x02010;related grade &#x02265;3 toxicities or hypertension while on maximal antihypertensive medications. Both patients and investigators were blinded to the drug (axitinib or placebo) used in dose titration. Study treatments were administered to patients in 4&#x02010;week cycles.</p><p>The primary endpoint of the study, the comparison of the objective response rate between the two randomized arms, has been reported previously.<xref rid="cas13232-bib-0006" ref-type="ref">6</xref> Secondary endpoints included PFS, OS and safety.</p><p>The study protocol was approved at each study center by an institutional review board or independent ethics committee, and the study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization guidelines on Good Clinical Practice, and applicable local regulatory requirements. Written, informed consent was obtained from each patient.</p></sec><sec id="cas13232-sec-0004"><title>Assessments</title><p>Radiological tumor assessments were conducted by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 at screening; after 8, 16 and 24&#x000a0;weeks of treatment; and every 12&#x000a0;weeks thereafter. Safety was monitored throughout the study and AE were graded per NCI&#x02010;CTCAE v3.0. Blood pressure was monitored at each clinic visit and at home by patients twice daily before study drug administration. Survival status was collected every 3&#x000a0;months after the follow&#x02010;up study visit, which was 28&#x000a0;days after the last dose.</p></sec><sec id="cas13232-sec-0005"><title>Statistical analyses</title><p>The calculation of the sample size required for the primary endpoint and statistical analyses have been described previously.<xref rid="cas13232-bib-0006" ref-type="ref">6</xref> Median OS, survival rate, and their 95% CI were estimated using the Kaplan&#x02013;Meier method, and comparisons between Japanese versus non&#x02010;Japanese patients and by ECOG PS (0 <italic>vs</italic> &#x02265;1) were done using unstratified and stratified log&#x02010;rank tests, respectively, and hazard ratio (HR) and 95% CI were provided. <italic>Ad hoc</italic> analyses to assess baseline predictive factors were performed using the Cox proportional hazard model. Each variable was tested in a univariate analysis with the Wald test, and the final model was constructed using a stepwise procedure with a 5% significance level.</p></sec></sec><sec id="cas13232-sec-0006"><title>Results</title><sec id="cas13232-sec-0007"><title>Patient disposition, baseline characteristics and treatment</title><p>A total of 44&#x000a0;patients from Japan and 169 non&#x02010;Japanese patients from five other countries were enrolled in the study (Fig.&#x000a0;<xref rid="cas13232-fig-0001" ref-type="fig">1</xref>). One Japanese and nine non&#x02010;Japanese patients discontinued the study treatment during the lead&#x02010;in period because of disease progression, withdrawal of consent, or other reasons. After the lead&#x02010;in period, 11 Japanese and 101 non&#x02010;Japanese patients were assigned to either the axitinib or the placebo titration arm. In total, 32 Japanese and 59 non&#x02010;Japanese continued axitinib in the non&#x02010;randomized arm. At the time of follow&#x02010;up analysis (data cutoff date: 4 November 2014), 36 of 44 (82%) Japanese and 157 of 169 (93%) non&#x02010;Japanese patients had discontinued study treatment, mostly because of disease progression.</p><fig fig-type="Figure" xml:lang="en" id="cas13232-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Trial profile: (a) Japanese and (b) non&#x02010;Japanese patients. <styled-content style="fixed-case">AE</styled-content>, adverse event.</p></caption><graphic id="nlm-graphic-3" xlink:href="CAS-108-1231-g001"/></fig><p>The demographics and baseline characteristics of overall Japanese versus non&#x02010;Japanese patients are summarized in Table&#x000a0;<xref rid="cas13232-tbl-0001" ref-type="table-wrap">1</xref>.<xref rid="cas13232-bib-0011" ref-type="ref">11</xref> The median age of Japanese patients was 5&#x000a0;years older than non&#x02010;Japanese patients, but Japanese patients had more favorable baseline prognosis, with ECOG PS 0, fewer metastases and smaller tumor size. There was no significant difference in the percentage of Japanese versus non&#x02010;Japanese patients who had prior nephrectomy.</p><table-wrap id="cas13232-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographics and baseline characteristics in the overall Japanese versus non&#x02010;Japanese patients<xref ref-type="fn" rid="cas13232-note-0003">&#x02020;</xref>
</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Japanese</th><th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Non&#x02010;Japanese</th><th align="center" rowspan="2" valign="top" colspan="1">
<italic>P&#x02010;</italic>value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">
<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>44</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>169</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, median (range), years</td><td align="char" char=" " rowspan="1" colspan="1">66 (42&#x02013;81)</td><td align="char" char=" " rowspan="1" colspan="1">61 (28&#x02013;87)</td><td align="char" char="." rowspan="1" colspan="1">0.0231<xref ref-type="fn" rid="cas13232-note-0003">&#x02021;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">Sex, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="char" char=" " rowspan="1" colspan="1">30 (68)</td><td align="char" char=" " rowspan="1" colspan="1">113 (67)</td><td align="char" char="." rowspan="1" colspan="1">1.0000<xref ref-type="fn" rid="cas13232-note-0003">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="char" char=" " rowspan="1" colspan="1">14 (32)</td><td align="char" char=" " rowspan="1" colspan="1">56 (33)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Race, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">162 (96)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="fn" rid="cas13232-note-0003">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Asian</td><td align="char" char=" " rowspan="1" colspan="1">44 (100)</td><td align="char" char=" " rowspan="1" colspan="1">2 (1)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">2 (1)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">3 (2)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Height, mean (SD), cm</td><td align="char" char=" " rowspan="1" colspan="1">162 (9)</td><td align="char" char=" " rowspan="1" colspan="1">172 (10)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="fn" rid="cas13232-note-0003">&#x02021;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, mean (SD), kg</td><td align="char" char=" " rowspan="1" colspan="1">61 (12)</td><td align="char" char=" " rowspan="1" colspan="1">83 (18)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="fn" rid="cas13232-note-0003">&#x02021;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">ECOG PS, <italic>n</italic> (%)<xref ref-type="fn" rid="cas13232-note-0003">&#x000b6;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">37 (84)</td><td align="char" char=" " rowspan="1" colspan="1">99 (59)</td><td align="char" char="." rowspan="1" colspan="1">0.0015<xref ref-type="fn" rid="cas13232-note-0003">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;1</td><td align="char" char=" " rowspan="1" colspan="1">7 (16)</td><td align="char" char=" " rowspan="1" colspan="1">70 (41)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Prior nephrectomy, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char=" " rowspan="1" colspan="1">37 (84)</td><td align="char" char=" " rowspan="1" colspan="1">146 (86)</td><td align="char" char="." rowspan="1" colspan="1">0.8077<xref ref-type="fn" rid="cas13232-note-0003">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char=" " rowspan="1" colspan="1">7 (16)</td><td align="char" char=" " rowspan="1" colspan="1">23 (14)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Number of metastatic sites, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td><td align="char" char=" " rowspan="1" colspan="1">17 (39)</td><td align="char" char=" " rowspan="1" colspan="1">24 (14)</td><td align="char" char="." rowspan="1" colspan="1">0.0003<xref ref-type="fn" rid="cas13232-note-0003">&#x02020;&#x02020;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td><td align="char" char=" " rowspan="1" colspan="1">13 (30)</td><td align="char" char=" " rowspan="1" colspan="1">44 (26)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3</td><td align="char" char=" " rowspan="1" colspan="1">6 (14)</td><td align="char" char=" " rowspan="1" colspan="1">46 (27)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;4</td><td align="char" char=" " rowspan="1" colspan="1">8 (18)</td><td align="char" char=" " rowspan="1" colspan="1">55 (33)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Metastatic sites (lung versus lung&#x000a0;+&#x000a0;others), <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lung only</td><td align="char" char=" " rowspan="1" colspan="1">9 (20)</td><td align="char" char=" " rowspan="1" colspan="1">16 (9)</td><td align="char" char="." rowspan="1" colspan="1">0.0627<xref ref-type="fn" rid="cas13232-note-0003">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lung&#x000a0;+&#x000a0;others</td><td align="char" char=" " rowspan="1" colspan="1">35 (80)</td><td align="char" char=" " rowspan="1" colspan="1">153 (91)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Metastatic sites (individual), <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lung</td><td align="char" char=" " rowspan="1" colspan="1">30 (68)</td><td align="char" char=" " rowspan="1" colspan="1">119 (70)</td><td align="char" char="." rowspan="1" colspan="1">0.8538<xref ref-type="fn" rid="cas13232-note-0003">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lymph node</td><td align="char" char=" " rowspan="1" colspan="1">13 (30)</td><td align="char" char=" " rowspan="1" colspan="1">86 (51)</td><td align="char" char="." rowspan="1" colspan="1">0.0169<xref ref-type="fn" rid="cas13232-note-0003">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Kidney</td><td align="char" char=" " rowspan="1" colspan="1">13 (30)</td><td align="char" char=" " rowspan="1" colspan="1">37 (22)</td><td align="char" char="." rowspan="1" colspan="1">0.3194<xref ref-type="fn" rid="cas13232-note-0003">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Liver</td><td align="char" char=" " rowspan="1" colspan="1">6 (14)</td><td align="char" char=" " rowspan="1" colspan="1">47 (28)</td><td align="char" char="." rowspan="1" colspan="1">0.0766<xref ref-type="fn" rid="cas13232-note-0003">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Adrenal</td><td align="char" char=" " rowspan="1" colspan="1">3 (7)</td><td align="char" char=" " rowspan="1" colspan="1">46 (27)</td><td align="char" char="." rowspan="1" colspan="1">0.0042<xref ref-type="fn" rid="cas13232-note-0003">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Bone</td><td align="char" char=" " rowspan="1" colspan="1">7 (16)</td><td align="char" char=" " rowspan="1" colspan="1">30 (18)</td><td align="char" char="." rowspan="1" colspan="1">1.0000<xref ref-type="fn" rid="cas13232-note-0003">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pancreas</td><td align="char" char=" " rowspan="1" colspan="1">1 (2)</td><td align="char" char=" " rowspan="1" colspan="1">4 (2)</td><td align="char" char="." rowspan="1" colspan="1">1.0000<xref ref-type="fn" rid="cas13232-note-0003">&#x000a7;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">Time from histopathological diagnosis to treatment, median (range), weeks</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">56 (0.1&#x02013;952)</td><td align="char" char=" " rowspan="1" colspan="1">23 (0.1&#x02013;1338)</td><td align="char" char="." rowspan="1" colspan="1">0.9223<xref ref-type="fn" rid="cas13232-note-0003">&#x02021;&#x02021;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">Time from metastatic diagnosis to treatment, median (range), weeks</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">7 (0.9&#x02013;263)</td><td align="char" char=" " rowspan="1" colspan="1">8 (0.7&#x02013;456)</td><td align="char" char="." rowspan="1" colspan="1">0.4476<xref ref-type="fn" rid="cas13232-note-0003">&#x02021;&#x02021;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">Sum of longest diameter for target lesion, median (range), mm</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">75 (10&#x02013;376)</td><td align="char" char=" " rowspan="1" colspan="1">99 (10&#x02013;466)</td><td align="char" char="." rowspan="1" colspan="1">0.0013<xref ref-type="fn" rid="cas13232-note-0003">&#x02021;&#x02021;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">Presence of metastases (<italic>de novo</italic>) at initial diagnosis, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char=" " rowspan="1" colspan="1">25 (57)</td><td align="char" char=" " rowspan="1" colspan="1">94 (56)</td><td align="char" char="." rowspan="1" colspan="1">1.0000<xref ref-type="fn" rid="cas13232-note-0003">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char=" " rowspan="1" colspan="1">19 (43)</td><td align="char" char=" " rowspan="1" colspan="1">75 (44)</td><td align="char" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="cas13232-note-0003"><p>&#x02020;Tomita Y <italic>et&#x000a0;al</italic>. (2011).<xref rid="cas13232-bib-0011" ref-type="ref">11</xref> Available from <ext-link ext-link-type="uri" xlink:href="http://jjco.oxfordjournals.org/content/46/11/1031.long">http://jjco.oxfordjournals.org/content/46/11/1031.long</ext-link>. &#x02021;Using Student's <italic>t</italic>&#x02010;test. &#x000a7;Using Fisher's exact test. &#x000b6;Per case report forms and the last measure taken prior to dosing. One non&#x02010;Japanese patient had ECOG PS 2. &#x02020;&#x02020;Using Cochran&#x02013;Armitage trend exact test. &#x02021;&#x02021;Using Wilcoxon test. ECOG PS, Eastern Cooperative Oncology Group performance status; SD, standard deviation.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Because a significantly higher percentage of Japanese than non&#x02010;Japanese patients (73 <italic>vs</italic> 35%) were not assigned to dose titration arms and remained on or below the starting 5 mg b.i.d. in the non&#x02010;randomized arm, patient baseline characteristics were also compared between Japanese and non&#x02010;Japanese patients in the non&#x02010;randomized arm (Table&#x000a0;<xref rid="cas13232-tbl-0002" ref-type="table-wrap">2</xref>). As in the overall population, Japanese patients in the non&#x02010;randomized arm had more favorable prognosis at baseline than non&#x02010;Japanese patients, but there was no longer any significant difference between the two groups with regard to patient age.</p><table-wrap id="cas13232-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Demographics and baseline characteristics in Japanese versus non&#x02010;Japanese patients in the non&#x02010;randomized arm</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Japanese</th><th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Non&#x02010;Japanese</th><th align="center" rowspan="2" valign="top" colspan="1">
<italic>P&#x02010;</italic>value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">
<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>32</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>59</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, median (range), years</td><td align="char" char=" " rowspan="1" colspan="1">63 (43&#x02013;79)</td><td align="char" char=" " rowspan="1" colspan="1">63 (47&#x02013;87)</td><td align="char" char="." rowspan="1" colspan="1">0.7777<xref ref-type="fn" rid="cas13232-note-0004">&#x02020;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">Sex, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="char" char=" " rowspan="1" colspan="1">19 (59)</td><td align="char" char=" " rowspan="1" colspan="1">36 (61)</td><td align="char" char="." rowspan="1" colspan="1">1.0000<xref ref-type="fn" rid="cas13232-note-0004">&#x02021;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="char" char=" " rowspan="1" colspan="1">13 (41)</td><td align="char" char=" " rowspan="1" colspan="1">23 (39)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Race, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">55 (93)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="fn" rid="cas13232-note-0004">&#x02021;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Asian</td><td align="char" char=" " rowspan="1" colspan="1">32 (100)</td><td align="char" char=" " rowspan="1" colspan="1">1 (2)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">2 (3)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">1 (2)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Height, mean (SD), cm</td><td align="char" char=" " rowspan="1" colspan="1">161 (9)</td><td align="char" char=" " rowspan="1" colspan="1">171 (10)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="fn" rid="cas13232-note-0004">&#x02020;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, mean (SD), kg</td><td align="char" char=" " rowspan="1" colspan="1">61 (13)</td><td align="char" char=" " rowspan="1" colspan="1">87 (18)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001<xref ref-type="fn" rid="cas13232-note-0004">&#x02020;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">ECOG PS, <italic>n</italic> (%)<xref ref-type="fn" rid="cas13232-note-0004">&#x000b6;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">27 (84)</td><td align="char" char=" " rowspan="1" colspan="1">36 (61)</td><td align="char" char="." rowspan="1" colspan="1">0.0313<xref ref-type="fn" rid="cas13232-note-0004">&#x02021;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;1</td><td align="char" char=" " rowspan="1" colspan="1">5 (16)</td><td align="char" char=" " rowspan="1" colspan="1">23 (39)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Prior nephrectomy, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char=" " rowspan="1" colspan="1">28 (88)</td><td align="char" char=" " rowspan="1" colspan="1">53 (90)</td><td align="char" char="." rowspan="1" colspan="1">0.7367<xref ref-type="fn" rid="cas13232-note-0004">&#x02021;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char=" " rowspan="1" colspan="1">4 (13)</td><td align="char" char=" " rowspan="1" colspan="1">6 (10)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Number of metastatic sites, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td><td align="char" char=" " rowspan="1" colspan="1">13 (41)</td><td align="char" char=" " rowspan="1" colspan="1">9 (15)</td><td align="char" char="." rowspan="1" colspan="1">0.0045<xref ref-type="fn" rid="cas13232-note-0004">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td><td align="char" char=" " rowspan="1" colspan="1">10 (31)</td><td align="char" char=" " rowspan="1" colspan="1">14 (24)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3</td><td align="char" char=" " rowspan="1" colspan="1">3 (9)</td><td align="char" char=" " rowspan="1" colspan="1">18 (31)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;4</td><td align="char" char=" " rowspan="1" colspan="1">6 (19)</td><td align="char" char=" " rowspan="1" colspan="1">18 (31)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Metastatic sites (lung versus lung&#x000a0;+&#x000a0;others), <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lung only</td><td align="char" char=" " rowspan="1" colspan="1">7 (22)</td><td align="char" char=" " rowspan="1" colspan="1">8 (14)</td><td align="char" char="." rowspan="1" colspan="1">0.3781<xref ref-type="fn" rid="cas13232-note-0004">&#x02021;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lung&#x000a0;+&#x000a0;others</td><td align="char" char=" " rowspan="1" colspan="1">25 (78)</td><td align="char" char=" " rowspan="1" colspan="1">51 (86)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Metastatic sites (individual), <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lung</td><td align="char" char=" " rowspan="1" colspan="1">20 (63)</td><td align="char" char=" " rowspan="1" colspan="1">47 (80)</td><td align="char" char="." rowspan="1" colspan="1">0.0869<xref ref-type="fn" rid="cas13232-note-0004">&#x02021;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lymph node</td><td align="char" char=" " rowspan="1" colspan="1">7 (22)</td><td align="char" char=" " rowspan="1" colspan="1">29 (49)</td><td align="char" char="." rowspan="1" colspan="1">0.0137<xref ref-type="fn" rid="cas13232-note-0004">&#x02021;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Kidney</td><td align="char" char=" " rowspan="1" colspan="1">9 (28)</td><td align="char" char=" " rowspan="1" colspan="1">10 (17)</td><td align="char" char="." rowspan="1" colspan="1">0.2806<xref ref-type="fn" rid="cas13232-note-0004">&#x02021;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Liver</td><td align="char" char=" " rowspan="1" colspan="1">5 (16)</td><td align="char" char=" " rowspan="1" colspan="1">14 (24)</td><td align="char" char="." rowspan="1" colspan="1">0.4281<xref ref-type="fn" rid="cas13232-note-0004">&#x02021;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Adrenal</td><td align="char" char=" " rowspan="1" colspan="1">2 (6)</td><td align="char" char=" " rowspan="1" colspan="1">15 (25)</td><td align="char" char="." rowspan="1" colspan="1">0.0267<xref ref-type="fn" rid="cas13232-note-0004">&#x02021;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Bone</td><td align="char" char=" " rowspan="1" colspan="1">4 (13)</td><td align="char" char=" " rowspan="1" colspan="1">9 (15)</td><td align="char" char="." rowspan="1" colspan="1">1.0000<xref ref-type="fn" rid="cas13232-note-0004">&#x02021;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pancreas</td><td align="char" char=" " rowspan="1" colspan="1">1 (3)</td><td align="char" char=" " rowspan="1" colspan="1">2 (3)</td><td align="char" char="." rowspan="1" colspan="1">1.0000<xref ref-type="fn" rid="cas13232-note-0004">&#x02021;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">Time from histopathological diagnosis to treatment, median (range), weeks</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">56 (0.1&#x02013;952)</td><td align="char" char=" " rowspan="1" colspan="1">42 (0.1&#x02013;1338)</td><td align="char" char="." rowspan="1" colspan="1">0.8127<xref ref-type="fn" rid="cas13232-note-0004">&#x02020;&#x02020;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">Time from metastatic diagnosis to treatment, median (range), weeks</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">7 (1.3&#x02013;263)</td><td align="char" char=" " rowspan="1" colspan="1">9 (1.3&#x02013;325)</td><td align="char" char="." rowspan="1" colspan="1">0.2854<xref ref-type="fn" rid="cas13232-note-0004">&#x02020;&#x02020;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">Sum of longest diameter for target lesion, median (range), mm</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">65 (11&#x02013;376)</td><td align="char" char=" " rowspan="1" colspan="1">89 (10&#x02013;379)</td><td align="char" char="." rowspan="1" colspan="1">0.0218<xref ref-type="fn" rid="cas13232-note-0004">&#x02020;&#x02020;</xref>
</td></tr><tr><td align="left" colspan="4" rowspan="1">Presence of metastases (<italic>de novo</italic>) at initial diagnosis, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char=" " rowspan="1" colspan="1">19 (59)</td><td align="char" char=" " rowspan="1" colspan="1">34 (58)</td><td align="char" char="." rowspan="1" colspan="1">1.0000<xref ref-type="fn" rid="cas13232-note-0004">&#x02021;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char=" " rowspan="1" colspan="1">13 (41)</td><td align="char" char=" " rowspan="1" colspan="1">25 (42)</td><td align="char" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="cas13232-note-0004"><p>&#x02020;Using Student's <italic>t</italic>&#x02010;test. &#x02021;Using Fisher's exact test. &#x000b6;Per case report forms and the last measure taken prior to dosing. One non&#x02010;Japanese patient had ECOG PS 2. &#x000a7;Using Cochran&#x02013;Armitage trend exact test. &#x02020;&#x02020;Using Wilcoxon test. ECOG PS, Eastern Cooperative Oncology Group performance status; SD, standard deviation.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Treatment duration was comparable between the axitinib titration, the placebo titration and the non&#x02010;randomized arms among non&#x02010;Japanese patients, as previously reported.<xref rid="cas13232-bib-0011" ref-type="ref">11</xref> However, among Japanese patients, treatment duration was substantially longer with the axitinib titration and non&#x02010;randomized arm than with the placebo titration arm. In general, Japanese patients received treatment longer than non&#x02010;Japanese patients, and had more frequent dose reductions. Relative dose intensity was also lower among Japanese than non&#x02010;Japanese patients.</p></sec><sec id="cas13232-sec-0008"><title>Efficacy</title><p>At the data cutoff date for the follow&#x02010;up analysis, the median duration of follow&#x02010;up was 33&#x000a0;months (range, 1&#x02013;60) in all patients and 44&#x000a0;months (range, 5&#x02013;51) in Japanese patients. Fewer than half (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>16 of 44) of Japanese patients had died, and, thus, median OS was not reached (95% CI, 38.8&#x02013;not estimable). The HR for OS in Japanese versus non&#x02010;Japanese patients was 0.489 (95% CI, 0.281&#x02013;0.850; stratified, two&#x02010;sided <italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.0099; Fig.&#x000a0;<xref rid="cas13232-fig-0002" ref-type="fig">2</xref>). Estimated survival probability (95% CI) in Japanese patients was 86.4% (76.2&#x02013;96.5) at 1&#x000a0;year, 75.0% (62.2&#x02013;87.8) at 2&#x000a0;years and 68.2% (54.4&#x02013;81.9) at 3&#x000a0;years (Table&#x000a0;<xref rid="cas13232-tbl-0003" ref-type="table-wrap">3</xref>).</p><fig fig-type="Figure" xml:lang="en" id="cas13232-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Kaplan&#x02013;Meier estimates for overall survival in Japanese and non&#x02010;Japanese patients. <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">HR</styled-content>, hazard ratio; mo, month; <styled-content style="fixed-case">mOS</styled-content>, median overall survival, <styled-content style="fixed-case">NE</styled-content>, not estimable.</p></caption><graphic id="nlm-graphic-5" xlink:href="CAS-108-1231-g002"/></fig><table-wrap id="cas13232-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Survival probability at 1, 2 and 3&#x000a0;years in Japanese versus non&#x02010;Japanese patients</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Survival probability, % (95% CI)</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Total</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">ECOG PS 0</th><th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">ECOG PS &#x02265;1</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">Japanese <italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>44</th><th align="center" valign="top" rowspan="1" colspan="1">Non&#x02010;Japanese <italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>169</th><th align="center" valign="top" rowspan="1" colspan="1">Japanese <italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>37</th><th align="center" valign="top" rowspan="1" colspan="1">Non&#x02010;Japanese <italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>99</th><th align="center" valign="top" rowspan="1" colspan="1">Japanese <italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>7</th><th align="center" valign="top" rowspan="1" colspan="1">Non&#x02010;Japanese <italic>n</italic>&#x000a0;=&#x000a0;70</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1&#x02010;year</td><td align="char" char=" " rowspan="1" colspan="1">86.4 (76.2&#x02013;96.5)</td><td align="char" char=" " rowspan="1" colspan="1">75.1 (68.4&#x02013;81.8)</td><td align="char" char=" " rowspan="1" colspan="1">91.9 (83.1&#x02013;100.0)</td><td align="char" char=" " rowspan="1" colspan="1">84.3 (77.0&#x02013;91.6)</td><td align="char" char=" " rowspan="1" colspan="1">57.1 (20.5&#x02013;93.8)</td><td align="char" char=" " rowspan="1" colspan="1">61.4 (49.5&#x02013;73.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x02010;year</td><td align="char" char=" " rowspan="1" colspan="1">75.0 (62.2&#x02013;87.8)</td><td align="char" char=" " rowspan="1" colspan="1">62.1 (54.5&#x02013;69.7)</td><td align="char" char=" " rowspan="1" colspan="1">81.1 (68.5&#x02013;93.7)</td><td align="char" char=" " rowspan="1" colspan="1">71.0 (61.8&#x02013;80.3)</td><td align="char" char=" " rowspan="1" colspan="1">42.9 (6.2&#x02013;79.5)</td><td align="char" char=" " rowspan="1" colspan="1">48.8 (36.6&#x02013;61.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">3&#x02010;year</td><td align="char" char=" " rowspan="1" colspan="1">68.2 (54.4&#x02013;81.9)</td><td align="char" char=" " rowspan="1" colspan="1">47.2 (39.3&#x02013;55.1)</td><td align="char" char=" " rowspan="1" colspan="1">75.7 (61.9&#x02013;89.5)</td><td align="char" char=" " rowspan="1" colspan="1">58.2 (47.9&#x02013;68.4)</td><td align="char" char=" " rowspan="1" colspan="1">28.6 (0&#x02013;62.0)</td><td align="char" char=" " rowspan="1" colspan="1">31.5 (20.1&#x02013;42.9)</td></tr></tbody></table><table-wrap-foot><fn id="cas13232-note-0005"><p>CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>A total of 107 of 169 (63%) non&#x02010;Japanese patients had died at the cutoff date and 62 were censored. Median OS among non&#x02010;Japanese patients was 33.9&#x000a0;months (95% CI, 28.9&#x02013;42.7), with generally lower estimated 1&#x02010;year, 2&#x02010;year and 3&#x02010;year survival probability than for Japanese patients (Table&#x000a0;<xref rid="cas13232-tbl-0003" ref-type="table-wrap">3</xref>).</p><p>Because a higher percentage of Japanese patients had ECOG PS 0 compared with non&#x02010;Japanese patients, OS was compared between Japanese and non&#x02010;Japanese patients after stratifying for ECOG PS (Fig.&#x000a0;<xref rid="cas13232-fig-0003" ref-type="fig">3</xref>). Median OS was not estimable in Japanese patients with ECOG PS 0 compared with 42.7&#x000a0;months (95% CI, 34.5&#x02013;52.6) in non&#x02010;Japanese patients with ECOG PS 0. The HR (Japanese versus non&#x02010;Japanese patients) was 0.451 (95% CI, 0.235&#x02013;0.866; unstratified, two&#x02010;sided <italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.0140). However, among those with ECOG PS &#x02265;1, there was no significant difference in OS between Japanese and non&#x02010;Japanese patients. Similarly, 1&#x02010;year, 2&#x02010;year and 3&#x02010;year survival probability was higher in Japanese than non&#x02010;Japanese patients with ECOG PS 0, whereas no differences were observed between Japanese and non&#x02010;Japanese patients when comparing those with ECOG PS &#x02265;1 (Table&#x000a0;<xref rid="cas13232-tbl-0003" ref-type="table-wrap">3</xref>).</p><fig fig-type="Figure" xml:lang="en" id="cas13232-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Kaplan&#x02013;Meier estimates for overall survival stratified by <styled-content style="fixed-case">ECOG PS</styled-content>: (a) <styled-content style="fixed-case">ECOG PS</styled-content> 0 in Japanese and non&#x02010;Japanese patients and (b) <styled-content style="fixed-case">ECOG PS</styled-content> &#x02265;1 in Japanese and non&#x02010;Japanese patients. <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">ECOG PS</styled-content>, Eastern Cooperative Oncology Group performance status; <styled-content style="fixed-case">HR</styled-content>, hazard ratio; mo, month; <styled-content style="fixed-case">mOS</styled-content>, median overall survival; <styled-content style="fixed-case">NE</styled-content>, not estimable.</p></caption><graphic id="nlm-graphic-7" xlink:href="CAS-108-1231-g003"/></fig><p>The efficacy outcomes (PFS and OS) between Japanese and non&#x02010;Japanese patients were additionally evaluated in the non&#x02010;randomized arm because more Japanese patients were in the non&#x02010;randomized than randomized arm. Comparable to the results obtained with the overall Japanese versus non&#x02010;Japanese patients, PFS and OS (Fig.&#x000a0;<xref rid="cas13232-fig-0004" ref-type="fig">4</xref>a,b, respectively) were significantly longer in Japanese than non&#x02010;Japanese patients in the non&#x02010;randomized arm. Furthermore, 1&#x02010;year, 2&#x02010;year and 3&#x02010;year survival probabilities were substantially higher among Japanese than non&#x02010;Japanese patients in the non&#x02010;randomized arm (data not shown).</p><fig fig-type="Figure" xml:lang="en" id="cas13232-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Kaplan&#x02013;Meier estimates for (a) progression&#x02010;fee survival and (b) overall survival in Japanese and non&#x02010;Japanese patients in the non&#x02010;randomized arm. <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">HR</styled-content>, hazard ratio; mo, month; <styled-content style="fixed-case">mOS</styled-content>, median overall survival; <styled-content style="fixed-case">mPFS</styled-content>, median progression&#x02010;free survival; <styled-content style="fixed-case">NE</styled-content>, not estimable.</p></caption><graphic id="nlm-graphic-9" xlink:href="CAS-108-1231-g004"/></fig></sec><sec id="cas13232-sec-0009"><title>Follow&#x02010;up systemic therapy</title><p>A higher percentage of Japanese than non&#x02010;Japanese patients received any follow&#x02010;up systemic therapy (75 <italic>vs</italic> 52%; Table&#x000a0;<xref rid="cas13232-tbl-0004" ref-type="table-wrap">4</xref>). There was a tendency for Japanese patients to receive more frequent follow&#x02010;up systemic therapies than non&#x02010;Japanese patients: 31, 11 and 14% of Japanese patients received two, three or more than four follow&#x02010;up systemic therapies, respectively, compared with 11, 8 and 3% of non&#x02010;Japanese patients. Everolimus, sunitinib and sorafenib were preferred follow&#x02010;up systemic therapeutic agents in Japan, whereas everolimus and sunitinib were most frequently used in non&#x02010;Japanese patients from other regions.</p><table-wrap id="cas13232-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Follow&#x02010;up systemic therapy in Japanese versus non&#x02010;Japanese patients</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Japanese</th><th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Non&#x02010;Japanese</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">
<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>36<xref ref-type="fn" rid="cas13232-note-0006">&#x02020;</xref>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>157<xref ref-type="fn" rid="cas13232-note-0006">&#x02020;</xref>
</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">Number of regimen, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Any</td><td align="char" char=" " rowspan="1" colspan="1">27 (75)</td><td align="char" char=" " rowspan="1" colspan="1">82 (52)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td><td align="char" char=" " rowspan="1" colspan="1">7 (19)</td><td align="char" char=" " rowspan="1" colspan="1">46 (29)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td><td align="char" char=" " rowspan="1" colspan="1">11 (31)</td><td align="char" char=" " rowspan="1" colspan="1">18 (11)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3</td><td align="char" char=" " rowspan="1" colspan="1">4 (11)</td><td align="char" char=" " rowspan="1" colspan="1">13 (8)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">4</td><td align="char" char=" " rowspan="1" colspan="1">4 (11)</td><td align="char" char=" " rowspan="1" colspan="1">4 (3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">5</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">1 (1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">6</td><td align="char" char=" " rowspan="1" colspan="1">1 (3)</td><td align="char" char=" " rowspan="1" colspan="1">0</td></tr><tr><td align="left" colspan="3" rowspan="1">Type of medication, <italic>n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Everolimus</td><td align="char" char=" " rowspan="1" colspan="1">16 (44)</td><td align="char" char=" " rowspan="1" colspan="1">35 (22)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sunitinib</td><td align="char" char=" " rowspan="1" colspan="1">9 (25)</td><td align="char" char=" " rowspan="1" colspan="1">34 (22)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sorafenib</td><td align="char" char=" " rowspan="1" colspan="1">9 (25)</td><td align="char" char=" " rowspan="1" colspan="1">9 (6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Axitinib</td><td align="char" char=" " rowspan="1" colspan="1">7 (19)</td><td align="char" char=" " rowspan="1" colspan="1">5 (3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Temsirolimus</td><td align="char" char=" " rowspan="1" colspan="1">6 (17)</td><td align="char" char=" " rowspan="1" colspan="1">8 (5)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Interferon&#x02010;&#x003b1;</td><td align="char" char=" " rowspan="1" colspan="1">4 (11)</td><td align="char" char=" " rowspan="1" colspan="1">4 (3)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pazopanib</td><td align="char" char=" " rowspan="1" colspan="1">3 (8)</td><td align="char" char=" " rowspan="1" colspan="1">17 (11)</td></tr></tbody></table><table-wrap-foot><fn id="cas13232-note-0006"><p>&#x02020;The number of patients who discontinued study treatment.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="cas13232-sec-0010"><title>Safety</title><p>As reported previously,<xref rid="cas13232-bib-0011" ref-type="ref">11</xref> hypertension, diarrhea and fatigue were the most common treatment&#x02010;emergent, all&#x02010;causality, all&#x02010;grade AE in both Japanese (91, 75 and 50%, respectively) and non&#x02010;Japanese (59, 56 and 50%, respectively) patients treated with axitinib in this updated analysis. Hand&#x02013;foot syndrome, hypothyroidism, dysphonia and proteinuria were also prevalent in both Japanese and non&#x02010;Japanese patients, but incidence rates were higher in Japanese (all&#x02010;grade: 73, 68, 68 and 64%, respectively) than non&#x02010;Japanese (all&#x02010;grade: 21, 26, 33 and 22%, respectively) patients. Compared with the previous safety analysis, the nature of AE remained the same and no new AE of concern were observed, but the incidence rates for several AE increased slightly among Japanese and non&#x02010;Japanese patients. The AE that increased by &#x02265;5% were nasopharyngitis (from 32% to 39%) and nausea (from 25% to 30%) in Japanese patients, with none increasing by &#x02265;5% in non&#x02010;Japanese patients.</p></sec><sec id="cas13232-sec-0011"><title>Predictive factors for overall survival</title><p>The predictive potential of baseline characteristics for OS was evaluated in all 213&#x000a0;patients. The univariate analysis identified several baseline characteristics that were associated with longer OS: Asian race, ECOG PS 0, prior nephrectomy, fewer number of metastases, metastasis to lung only (compared with metastasis to lung plus other organs), time from histopathological diagnosis to treatment &#x02265;1&#x000a0;year, sum of the longest diameter of target lesions (i.e. baseline tumor burden) &#x02264;median (89&#x000a0;mm in all patients), absence of <italic>de novo</italic> metastasis at initial diagnosis, baseline lactate dehydrogenase &#x02264;1.5&#x000d7; upper limit of normal, and baseline hemoglobin &#x02265;lower limit of normal (Table&#x000a0;<xref rid="cas13232-tbl-0005" ref-type="table-wrap">5</xref>). A proportionality in median OS and HR was observed with regard to the number of metastatic sites: median OS was 57.2, 54.8, 38.8 and 22.9&#x000a0;months in patients with 1, 2, 3 and &#x02265;4 metastatic sites, respectively, with corresponding HR of 1, 1.366, 2.209 and 3.538. With regard to individual metastatic sites, involvement of lung, lymph node, liver, or bone was predictive of shorter survival (see Table&#x000a0;<xref rid="cas13232-sup-0001" ref-type="supplementary-material">S1</xref>). In the multivariate analysis, baseline ECOG PS 0, baseline tumor size &#x02264;median, and time from histopathological diagnosis to treatment &#x02265;1&#x000a0;year remained significant (<italic>P</italic>&#x000a0;&#x02264;&#x000a0;0.0003) predictors for longer OS (Table&#x000a0;<xref rid="cas13232-tbl-0006" ref-type="table-wrap">6</xref>).</p><table-wrap id="cas13232-tbl-0005" xml:lang="en" orientation="portrait" position="float"><label>Table 5</label><caption><p>Univariate analysis of predictive factors for overall survival in all patients (<italic>N</italic>&#x000a0;=&#x000a0;213)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">mOS, month (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1">Hazard ratio (95% CI)<xref ref-type="fn" rid="cas13232-note-0007">&#x02020;</xref>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P&#x02010;</italic>value<xref ref-type="fn" rid="cas13232-note-0007">&#x02021;</xref>
</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Age, years</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;65</td><td align="char" char="." rowspan="1" colspan="1">136</td><td align="char" char=" " rowspan="1" colspan="1">34.7 (24.7&#x02013;44.0)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;65</td><td align="char" char="." rowspan="1" colspan="1">77</td><td align="char" char=" " rowspan="1" colspan="1">47.5 (33.9&#x02013;NE)</td><td align="char" char=" " rowspan="1" colspan="1">0.692 (0.472&#x02013;1.014)</td><td align="char" char="." rowspan="1" colspan="1">0.0592</td></tr><tr><td align="left" colspan="5" rowspan="1">Sex</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="char" char="." rowspan="1" colspan="1">143</td><td align="char" char=" " rowspan="1" colspan="1">38.8 (32.3&#x02013;50.1)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="char" char="." rowspan="1" colspan="1">70</td><td align="char" char=" " rowspan="1" colspan="1">39.6 (27.6&#x02013;50.0)</td><td align="char" char=" " rowspan="1" colspan="1">1.115 (0.770&#x02013;1.616)</td><td align="char" char="." rowspan="1" colspan="1">0.5634</td></tr><tr><td align="left" colspan="5" rowspan="1">Race</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td><td align="char" char="." rowspan="1" colspan="1">162</td><td align="char" char=" " rowspan="1" colspan="1">33.9 (27.6&#x02013;42.8)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Asian</td><td align="char" char="." rowspan="1" colspan="1">46</td><td align="char" char=" " rowspan="1" colspan="1">NE (38.8&#x02013;NE)</td><td align="char" char=" " rowspan="1" colspan="1">0.489 (0.292&#x02013;0.820)</td><td align="char" char="." rowspan="1" colspan="1">0.0066</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black</td><td align="char" char="." rowspan="1" colspan="1">2</td><td align="char" char=" " rowspan="1" colspan="1">36.8 (33.0&#x02013;40.6)</td><td align="char" char=" " rowspan="1" colspan="1">1.327 (0.327&#x02013;5.396)</td><td align="char" char="." rowspan="1" colspan="1">0.6922</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char=" " rowspan="1" colspan="1">54.8 (4.1&#x02013;54.8)</td><td align="char" char=" " rowspan="1" colspan="1">0.818 (0.201&#x02013;3.321)</td><td align="char" char="." rowspan="1" colspan="1">0.7782</td></tr><tr><td align="left" colspan="5" rowspan="1">Body weight, kg</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02264;65</td><td align="char" char="." rowspan="1" colspan="1">56</td><td align="char" char=" " rowspan="1" colspan="1">39.6 (25.5&#x02013;52.6)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003e;65 to &#x02264;76</td><td align="char" char="." rowspan="1" colspan="1">51</td><td align="char" char=" " rowspan="1" colspan="1">39.3 (22.9&#x02013;NE)</td><td align="char" char=" " rowspan="1" colspan="1">0.883 (0.531&#x02013;1.470)</td><td align="char" char="." rowspan="1" colspan="1">0.6325</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003e;76 to &#x02264;89</td><td align="char" char="." rowspan="1" colspan="1">53</td><td align="char" char=" " rowspan="1" colspan="1">34.5 (24.7&#x02013;54.8)</td><td align="char" char=" " rowspan="1" colspan="1">0.868 (0.532&#x02013;1.417)</td><td align="char" char="." rowspan="1" colspan="1">0.5720</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003e;89</td><td align="char" char="." rowspan="1" colspan="1">53</td><td align="char" char=" " rowspan="1" colspan="1">41.6 (29.9&#x02013;NE)</td><td align="char" char=" " rowspan="1" colspan="1">0.866 (0.529&#x02013;1.418)</td><td align="char" char="." rowspan="1" colspan="1">0.5675</td></tr><tr><td align="left" colspan="5" rowspan="1">ECOG PS</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">0</td><td align="char" char="." rowspan="1" colspan="1">136</td><td align="char" char=" " rowspan="1" colspan="1">50.0 (40.6&#x02013;NE)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;1</td><td align="char" char="." rowspan="1" colspan="1">77</td><td align="char" char=" " rowspan="1" colspan="1">20.8 (11.7&#x02013;31.9)</td><td align="char" char=" " rowspan="1" colspan="1">2.484 (1.741&#x02013;3.543)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" colspan="5" rowspan="1">Prior nephrectomy</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char="." rowspan="1" colspan="1">183</td><td align="char" char=" " rowspan="1" colspan="1">42.5 (34.5&#x02013;50.3)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char=" " rowspan="1" colspan="1">21.6 (10.5&#x02013;34.1)</td><td align="char" char=" " rowspan="1" colspan="1">2.139 (1.367&#x02013;3.348)</td><td align="char" char="." rowspan="1" colspan="1">0.0009</td></tr><tr><td align="left" colspan="5" rowspan="1">Number of metastatic sites</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">1</td><td align="char" char="." rowspan="1" colspan="1">41</td><td align="char" char=" " rowspan="1" colspan="1">57.2 (50.0&#x02013;NE)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2</td><td align="char" char="." rowspan="1" colspan="1">57</td><td align="char" char=" " rowspan="1" colspan="1">54.8 (35.2&#x02013;NE)</td><td align="char" char=" " rowspan="1" colspan="1">1.366 (0.720&#x02013;2.591)</td><td align="char" char="." rowspan="1" colspan="1">0.3401</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">52</td><td align="char" char=" " rowspan="1" colspan="1">38.8 (24.8&#x02013;44.7)</td><td align="char" char=" " rowspan="1" colspan="1">2.209 (1.203&#x02013;4.058)</td><td align="char" char="." rowspan="1" colspan="1">0.0106</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;4</td><td align="char" char="." rowspan="1" colspan="1">63</td><td align="char" char=" " rowspan="1" colspan="1">22.9 (11.7&#x02013;32.7)</td><td align="char" char=" " rowspan="1" colspan="1">3.538 (1.980&#x02013;6.321)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" colspan="5" rowspan="1">Metastatic sites (lung versus lung&#x000a0;+&#x000a0;others)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lung only</td><td align="char" char="." rowspan="1" colspan="1">25</td><td align="char" char=" " rowspan="1" colspan="1">57.2 (37.8&#x02013;NE)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lung&#x000a0;+&#x000a0;others</td><td align="char" char="." rowspan="1" colspan="1">188</td><td align="char" char=" " rowspan="1" colspan="1">34.7 (28.9&#x02013;43.2)</td><td align="char" char=" " rowspan="1" colspan="1">2.057 (1.076&#x02013;3.930)</td><td align="char" char="." rowspan="1" colspan="1">0.0291</td></tr><tr><td align="left" colspan="5" rowspan="1">Time from histopathological diagnosis to treatment, years</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;1</td><td align="char" char="." rowspan="1" colspan="1">88</td><td align="char" char=" " rowspan="1" colspan="1">57.2 (42.7&#x02013;NE)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;1</td><td align="char" char="." rowspan="1" colspan="1">125</td><td align="char" char=" " rowspan="1" colspan="1">28.9 (17.6&#x02013;39.3)</td><td align="char" char=" " rowspan="1" colspan="1">2.270 (1.547&#x02013;3.330)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" colspan="5" rowspan="1">Time from metastatic diagnosis to treatment, years</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;1</td><td align="char" char="." rowspan="1" colspan="1">20</td><td align="char" char=" " rowspan="1" colspan="1">40.1 (24.7&#x02013;NE)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;1</td><td align="char" char="." rowspan="1" colspan="1">193</td><td align="char" char=" " rowspan="1" colspan="1">39.3 (32.6&#x02013;46.1)</td><td align="char" char=" " rowspan="1" colspan="1">1.050 (0.577&#x02013;1.908)</td><td align="char" char="." rowspan="1" colspan="1">0.8736</td></tr><tr><td align="left" colspan="5" rowspan="1">Sum of longest diameter for target lesion<xref ref-type="fn" rid="cas13232-note-0007">&#x000a7;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02264;Median<xref ref-type="fn" rid="cas13232-note-0007">&#x000b6;</xref>
</td><td align="char" char="." rowspan="1" colspan="1">107</td><td align="char" char=" " rowspan="1" colspan="1">54.8 (44.0&#x02013;NE)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003e;Median<xref ref-type="fn" rid="cas13232-note-0007">&#x000b6;</xref>
</td><td align="char" char="." rowspan="1" colspan="1">105</td><td align="char" char=" " rowspan="1" colspan="1">23.7 (14.5&#x02013;33.9)</td><td align="char" char=" " rowspan="1" colspan="1">2.624 (1.817&#x02013;3.789)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" colspan="5" rowspan="1">Presence of metastases (<italic>de novo</italic>) at initial diagnosis</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char="." rowspan="1" colspan="1">119</td><td align="char" char=" " rowspan="1" colspan="1">50.3 (40.1&#x02013;NE)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char="." rowspan="1" colspan="1">94</td><td align="char" char=" " rowspan="1" colspan="1">28.9 (19.5&#x02013;37.8)</td><td align="char" char=" " rowspan="1" colspan="1">2.019 (1.413&#x02013;2.885)</td><td align="char" char="." rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" colspan="5" rowspan="1">Baseline LDH<xref ref-type="fn" rid="cas13232-note-0007">&#x02020;&#x02020;</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02264;1.5&#x000a0;&#x000d7;&#x000a0;ULN</td><td align="char" char="." rowspan="1" colspan="1">198</td><td align="char" char=" " rowspan="1" colspan="1">40.6 (33.9&#x02013;47.5)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003e;1.5&#x000a0;&#x000d7;&#x000a0;ULN</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char=" " rowspan="1" colspan="1">9.8 (3.7&#x02013;30.4)</td><td align="char" char=" " rowspan="1" colspan="1">3.149 (1.588&#x02013;6.243)</td><td align="char" char="." rowspan="1" colspan="1">0.0010</td></tr><tr><td align="left" colspan="5" rowspan="1">Baseline hemoglobin</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;LLN</td><td align="char" char="." rowspan="1" colspan="1">119</td><td align="char" char=" " rowspan="1" colspan="1">43.2 (38.6&#x02013;57.2)</td><td align="char" char=" " rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;LLN</td><td align="char" char="." rowspan="1" colspan="1">94</td><td align="char" char=" " rowspan="1" colspan="1">30.4 (17.2&#x02013;40.6)</td><td align="char" char=" " rowspan="1" colspan="1">1.563 (1.097&#x02013;2.227)</td><td align="char" char="." rowspan="1" colspan="1">0.0135</td></tr></tbody></table><table-wrap-foot><fn fn-type="equal" id="cas13232-note-0007"><p>&#x02020;1 equals reference. &#x02021;Using Wald test. &#x000a7;One patient did not have measurable disease at baseline. &#x000b6;Median equals 89&#x000a0;mm in all patients. &#x02020;&#x02020;Values were missing for 4&#x000a0;patients. CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; LLN, lower limit of normal; mOS, median overall survival; NE, not estimable; ULN, upper limit of normal.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="cas13232-tbl-0006" xml:lang="en" orientation="portrait" position="float"><label>Table 6</label><caption><p>Multivariate analysis<xref ref-type="fn" rid="cas13232-note-0008">&#x02020;</xref> of predictive factors for overall survival in all patients (<italic>N</italic>&#x000a0;=&#x000a0;213)<xref ref-type="fn" rid="cas13232-note-0008">&#x02021;</xref>
</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Hazard ratio (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>P&#x02010;</italic>value<xref ref-type="fn" rid="cas13232-note-0008">&#x000a7;</xref>
</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">ECOG PS</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;1 <italic>vs</italic> 0</td><td align="char" char=" " rowspan="1" colspan="1">1.956 (1.356&#x02013;2.822)</td><td align="char" char="." rowspan="1" colspan="1">0.0003</td></tr><tr><td align="left" colspan="3" rowspan="1">Time from histopathological diagnosis to treatment, years</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;1 <italic>vs</italic> &#x02265;1</td><td align="char" char=" " rowspan="1" colspan="1">2.079 (1.410&#x02013;3.065)</td><td align="char" char="." rowspan="1" colspan="1">0.0002</td></tr><tr><td align="left" colspan="3" rowspan="1">Sum of longest diameter for target lesion</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003e;Median<xref ref-type="fn" rid="cas13232-note-0008">&#x000b6;</xref> versus &#x02264;median<xref ref-type="fn" rid="cas13232-note-0008">&#x000b6;</xref>
</td><td align="char" char=" " rowspan="1" colspan="1">2.197 (1.503&#x02013;3.211)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table><table-wrap-foot><fn fn-type="equal" id="cas13232-note-0008"><p>&#x02020;Final model constructed by a stepwise method with a 0.05 significance level. &#x02021;Analysis based on 208 patients because 1 patient did not have measurable disease at baseline and 4 patients did not have LDH data. &#x000a7;Using Wald test. &#x000b6;Median equals 89&#x000a0;mm in all patients. CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec></sec><sec id="cas13232-sec-0012"><title>Discussion</title><p>The previous subgroup analysis of this phase II trial of axitinib suggests that Japanese patients achieved better efficacy than non&#x02010;Japanese patients and there was a similar safety profile in first&#x02010;line treatment of metastatic RCC.<xref rid="cas13232-bib-0011" ref-type="ref">11</xref> The current analysis was conducted to further evaluate survival benefit of axitinib in Japanese versus non&#x02010;Japanese patients previously untreated for metastatic RCC. In addition, we have investigated predictive values of baseline characteristics for OS using the data from all 213 patients enrolled in this trial. The study found several key findings: first, OS was significantly (stratified HR 0.489; <italic>P</italic>&#x000a0;=&#x000a0;0.0099) longer in the overall Japanese than the overall non&#x02010;Japanese patients. Second, when comparing Japanese and non&#x02010;Japanese patients in the non&#x02010;randomized arm, PFS, OS and survival probability were significantly longer for Japanese than non&#x02010;Japanese patients, similar to the results seen in the overall Japanese versus non&#x02010;Japanese patients. The majority of Japanese patients were in the non&#x02010;randomized arm; thus, the longer PFS and OS in overall Japanese patients in the non&#x02010;randomized arm contributed to the longer PFS and OS in the overall Japanese patients. Third, no new safety concerns were observed in Japanese or non&#x02010;Japanese patients. Fourth, several baseline factors may be predictive for OS in patients treated with first&#x02010;line axitinib.</p><p>The reasons for longer OS and higher survival probability observed in axitinib&#x02010;treated Japanese than non&#x02010;Japanese patients, whether in the overall population or in the non&#x02010;randomized arm, are likely multifactorial and may include patient&#x02010;related factors, such as more favorable baseline characteristics (e.g. ECOG PS 0, small tumor size and fewer metastases), as shown in Tables&#x000a0;<xref rid="cas13232-tbl-0001" ref-type="table-wrap">1</xref> and <xref rid="cas13232-tbl-0002" ref-type="table-wrap">2</xref>. In addition, treatment&#x02010;related factors, such as longer treatment duration and more frequent use of follow&#x02010;up therapies, have undoubtedly contributed to the better clinical outcomes for Japanese patients. More favorable baseline characteristics of Japanese patients may be explained by early diagnosis of metastatic disease through rigorous and extensive medical examination of patients with RCC by Japanese physicians followed by immediate and frequent treatments. Despite longer duration of axitinib treatment, the updated safety assessments did not reveal any new AE of significance in Japanese patients. As previously described, the nature of AE was similar between Japanese and non&#x02010;Japanese patients, with minor differences in incidence rates for some AE.<xref rid="cas13232-bib-0011" ref-type="ref">11</xref> The pharmacokinetics seemingly did not contribute to the differences in axitinib efficacy between Japanese and non&#x02010;Japanese because the range for the maximum observed plasma concentration as well as drug exposure at steady&#x02010;state generally overlapped between Japanese and non&#x02010;Japanese patients.<xref rid="cas13232-bib-0011" ref-type="ref">11</xref>
</p><p>The current analysis confirmed that axitinib has antitumor activity in treatment&#x02010;na&#x000ef;ve Japanese patients with metastatic RCC. The 3&#x02010;year survival probability of 68.2% with first&#x02010;line axitinib and a median OS not reached after a median follow&#x02010;up of 44&#x000a0;months in Japanese patients are higher than that previously observed with sunitinib or sorafenib. For example, in treatment&#x02010;na&#x000ef;ve Japanese patients with metastatic RCC treated with sorafenib (<italic>n</italic>&#x000a0;=&#x000a0;172) or sunitinib (<italic>n</italic>&#x000a0;=&#x000a0;99) for &#x02265;2&#x000a0;months in a routine clinical setting, the 3&#x02010;year OS rate was 48.8% and the median OS was 33.1&#x000a0;months.<xref rid="cas13232-bib-0012" ref-type="ref">12</xref> In an open&#x02010;label phase&#x000a0;II study, the median OS was 33.1&#x000a0;months (95% CI, 14.8&#x02013;not reached) in 25 treatment&#x02010;na&#x000ef;ve Japanese patients with metastatic RCC treated with sunitinib 50&#x000a0;mg orally once daily on a 4&#x02010;week&#x02010;on/2&#x02010;week&#x02010;off schedule.<xref rid="cas13232-bib-0013" ref-type="ref">13</xref> Median OS in first&#x02010;line treatment with sorafenib or sunitinib in Japanese patients with metastatic RCC was less than 3&#x000a0;years in these reports, whereas, in the current study, median OS in first&#x02010;line treatment with axitinib exceeded 3&#x000a0;years (lower limit of 95% CI was 38.8&#x000a0;months). To date, there has been no report on median OS for Japanese patients treated with pazopanib since its approval in 2014 by the Ministry of Health, Labour and Welfare in Japan. Thus, cross&#x02010;study comparison of the limited data seems to suggest that axitinib may achieve a longer median OS compared with sorafenib or sunitinib in Japanese patients, but without a prospective head&#x02010;to&#x02010;head study no definitive conclusions can be drawn. Of note, in a prospective phase&#x000a0;II study of combination therapy of sorafenib and interferon&#x02010;&#x003b1; conducted in Japanese patients with metastatic RCC, the 3&#x02010;year survival rate was 64.5% and median OS, which had not been reached after median follow&#x02010;up of 21.3&#x000a0;months, without increasing the incidence of AE.<xref rid="cas13232-bib-0014" ref-type="ref">14</xref> A combination therapy of TKI, including axitinib, with immunotherapy may offer additional improvement in OS.</p><p>This study has some limitations. First, this was a post hoc exploratory analysis. Second, although the study clearly demonstrated the benefit of axitinib in treating Japanese patients with metastatic RCC in the first&#x02010;line setting, the effect of axitinib titration compared with placebo titration on efficacy outcomes could not be confirmed due to the small sample sizes in the axitinib and placebo titration arms (6 and 5&#x000a0;patients, respectively).</p><p>To date, there have not been any validated biomarkers that may help identify patients with metastatic RCC who would achieve better clinical outcomes from targeted therapies, including axitinib, in either first&#x02010;line or second&#x02010;line settings. The univariate analysis in this study has indicated several baseline characteristics to be potentially predictive of OS in treatment&#x02010;na&#x000ef;ve patients with metastatic RCC treated with axitinib. The factors were the same as those previously found to be strongly associated with PFS,<xref rid="cas13232-bib-0011" ref-type="ref">11</xref> except prior nephrectomy and baseline lactate dehydrogenase. In the multivariate analysis, baseline ECOG PS, time from histopathological diagnosis to treatment, and tumor burden remained significant. It is noteworthy that ECOG PS was found to be associated with improved OS, but not with PFS when other relevant factors were taken into account. Some of the factors that prolonged OS in Japanese patients treated with axitinib, such as prior nephrectomy, number of metastatic sites, or metastasis to liver, lymph node or bone, have also been reported to affect OS in Japanese patients treated with first&#x02010;line sunitinib or sorafenib in univariate analyses.<xref rid="cas13232-bib-0012" ref-type="ref">12</xref>, <xref rid="cas13232-bib-0015" ref-type="ref">15</xref> In these reports, the Memorial Sloan Kettering Cancer Center (MSKCC) classification,<xref rid="cas13232-bib-0016" ref-type="ref">16</xref> C&#x02010;reactive protein level and early tumor shrinkage, in addition to liver metastasis, were shown to be independently associated with OS in multivariate analyses. In the current study, blood samples for determination of serum calcium concentrations were not collected and, hence, the effect of the MSKCC or the International Metastatic Renal Cell Carcinoma Database Consortium<xref rid="cas13232-bib-0017" ref-type="ref">17</xref> classification could not be evaluated.</p><p>In conclusion, the current analysis confirmed that first&#x02010;line treatment of axitinib has clinical activity in Japanese patients with metastatic RCC, including a higher 3&#x02010;year survival rate and a significantly longer OS in Japanese than non&#x02010;Japanese patients. Such a long OS observed in Japanese patients with metastatic RCC has not been previously reported for this population. In addition, axitinib is safe and well tolerated in Japanese patients. Furthermore, the study identified several potential predictive factors for OS in patients treated with axitinib as first&#x02010;line therapy.</p></sec><sec id="cas13232-sec-0014"><title>Disclosure Statement</title><p>Mototsugu Oya has received research funding and honoraria from Pfizer, Novartis and Ono, and honoraria from Bayer. Yoshihiko Tomita has received research funding from Pfizer, and honoraria from Pfizer, Novartis, Ono and Bristol&#x02010;Myers Squibb. Satoshi Fukasawa has no conflict of interest to declare. Nobuo Shinohara has received research funding from Pfizer and Astellas, and honoraria from Pfizer, Bayer, Novartis and GlaxoSmithKline. Tomonori Habuchi has received research funding from Pfizer, Novartis, Bayer, Daiichi Sankyo, Chugai, AstraZeneca, Kyowa Hakko Kirin, Kissei, Torii, Astellas and Takeda, and honoraria from Pfizer, Novartis, Janssen, Takeda, Astellas and AstraZeneca. Brian I. Rini has served as a consultant for and received research funding from Pfizer. Yosuke Fujii, Yoichi Kamei, Yoshiko Umeyama and Angel H. Bair are employed by Pfizer and Umeyama and Bair own stock in Pfizer. Hirotsugu Uemura has received research funding from Pfizer, and honoraria from Pfizer, Bayer, Novartis, Ono and Bristol&#x02010;Myers Squibb. The study was sponsored by Pfizer. Pfizer was involved in study design, and collection, analysis and interpretation of the data. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publicaiton.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="cas13232-sup-0001"><caption><p>
<bold>Table&#x000a0;S1.</bold> Univariate analysis of baseline individual metastatic sites for overall survival in all patients (<italic>N</italic>&#x000a0;=&#x000a0;213).</p></caption><media xlink:href="CAS-108-1231-s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="cas13232-sec-0013"><title>Acknowledgments</title><p>We thank Hisanaga Ohashi of Pfizer for data collection and Hiroko Godai of Pfizer for data analysis. Medical writing support was provided by Mariko Nagashima of Engage Scientific Solutions (Southport, CT, USA) and was funded by Pfizer.</p></ack><ref-list content-type="cited-references" id="cas13232-bibl-0001"><title>References</title><ref id="cas13232-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cas13232-cit-0001">
<string-name>
<surname>Rini</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Escudier</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Tomczak</surname>
<given-names>P</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial</article-title>. <source>Lancet</source>
<year>2011</year>; <volume>378</volume>: <fpage>1931</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22056247</pub-id></mixed-citation></ref><ref id="cas13232-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cas13232-cit-0002">
<string-name>
<surname>Motzer</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Escudier</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Tomczak</surname>
<given-names>P</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Axitinib versus sorafenib as second&#x02010;line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial</article-title>. <source>Lancet Oncol</source>
<year>2013</year>; <volume>14</volume>: <fpage>552</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">23598172</pub-id></mixed-citation></ref><ref id="cas13232-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cas13232-cit-0003">
<string-name>
<surname>Hutson</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Lesovoy</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Shukri</surname>
<given-names>S</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Axitinib versus sorafenib as first&#x02010;line therapy in patients with metastatic renal&#x02010;cell carcinoma: a randomised open&#x02010;label phase 3 trial</article-title>. <source>Lancet Oncol</source>
<year>2013</year>; <volume>14</volume>: <fpage>1287</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">24206640</pub-id></mixed-citation></ref><ref id="cas13232-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cas13232-cit-0004">
<string-name>
<surname>Hutson</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Shukri</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Stus</surname>
<given-names>VP</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Axitinib versus sorafenib in first&#x02010;line metastatic renal cell carcinoma: overall survival from a randomized phase III trial</article-title>. <source>Clin Genitourin Cancer</source>
<year>2017</year>; <volume>15</volume>: <fpage>72</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">27498023</pub-id></mixed-citation></ref><ref id="cas13232-bib-0005"><label>5</label><mixed-citation publication-type="miscellaneous" id="cas13232-cit-0005">
<collab collab-type="authors">National Comprehensive Cancer Network</collab>
. <article-title>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Kidney Cancer version 3.2016</article-title>. <year>2016</year> [Cited 14 September 2016.] Available from URL: <ext-link ext-link-type="uri" xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf">https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf</ext-link>.</mixed-citation></ref><ref id="cas13232-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cas13232-cit-0006">
<string-name>
<surname>Rini</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Melichar</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ueda</surname>
<given-names>T</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Axitinib with or without dose titration for first&#x02010;line metastatic renal&#x02010;cell carcinoma: a randomised double&#x02010;blind phase 2 trial</article-title>. <source>Lancet Oncol</source>
<year>2013</year>; <volume>14</volume>: <fpage>1233</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">24140184</pub-id></mixed-citation></ref><ref id="cas13232-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cas13232-cit-0007">
<string-name>
<surname>Rini</surname>
<given-names>BI</given-names>
</string-name>, <string-name>
<surname>Tomita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Melichar</surname>
<given-names>B</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first&#x02010;line metastatic renal cell carcinoma</article-title>. <source>Clin Genitourin Cancer</source>
<year>2016</year>; <volume>14</volume>: <fpage>499</fpage>&#x02013;<lpage>503</lpage>.<pub-id pub-id-type="pmid">27236772</pub-id></mixed-citation></ref><ref id="cas13232-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cas13232-cit-0008">
<string-name>
<surname>Tomita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Uemura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Fujimoto</surname>
<given-names>H</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Key predictive factors of axitinib (AG&#x02010;013736)&#x02010;induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine&#x02010;refractory metastatic renal cell Carcinoma</article-title>. <source>Eur J Cancer</source>
<year>2011</year>; <volume>47</volume>: <fpage>2592</fpage>&#x02013;<lpage>602</lpage>.<pub-id pub-id-type="pmid">21889330</pub-id></mixed-citation></ref><ref id="cas13232-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cas13232-cit-0009">
<string-name>
<surname>Eto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Uemura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tomita</surname>
<given-names>Y</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine&#x02010;refractory metastatic renal cell carcinoma</article-title>. <source>Cancer Sci</source>
<year>2014</year>; <volume>105</volume>: <fpage>1576</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">25283266</pub-id></mixed-citation></ref><ref id="cas13232-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cas13232-cit-0010">
<string-name>
<surname>Ueda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Uemura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tomita</surname>
<given-names>Y</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial</article-title>. <source>Jpn J Clin Oncol</source>
<year>2013</year>; <volume>43</volume>: <fpage>616</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">23630366</pub-id></mixed-citation></ref><ref id="cas13232-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cas13232-cit-0011">
<string-name>
<surname>Tomita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fukasawa</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Oya</surname>
<given-names>M</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Key predictive factors for efficacy of axitinib in first&#x02010;line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double&#x02010;blind phase II study</article-title>. <source>Jpn J Clin Oncol</source>
<year>2016</year>; <volume>46</volume>: <fpage>1031</fpage>&#x02013;<lpage>41</lpage>.</mixed-citation></ref><ref id="cas13232-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cas13232-cit-0012">
<string-name>
<surname>Miyazaki</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Miyake</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Harada</surname>
<given-names>KI</given-names>
</string-name>, <string-name>
<surname>Inoue</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Fujisawa</surname>
<given-names>M</given-names>
</string-name>. <article-title>Prognostic outcome in patients treated with tyrosine kinase inhibitors as first&#x02010;line molecular&#x02010;targeted therapy for metastatic renal cell carcinoma: experience in real&#x02010;world clinical practice in Japan</article-title>. <source>Mol Clin Oncol</source>
<year>2015</year>; <volume>3</volume>: <fpage>601</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">26137274</pub-id></mixed-citation></ref><ref id="cas13232-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cas13232-cit-0013">
<string-name>
<surname>Tomita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shinohara</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yuasa</surname>
<given-names>T</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma</article-title>. <source>Jpn J Clin Oncol</source>
<year>2010</year>; <volume>40</volume>: <fpage>1166</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">20713418</pub-id></mixed-citation></ref><ref id="cas13232-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cas13232-cit-0014">
<string-name>
<surname>Eto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kawano</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hirao</surname>
<given-names>Y</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Phase II clinical trial of sorafenib plus interferon&#x02010;alpha treatment for patients with metastatic renal cell carcinoma in Japan</article-title>. <source>BMC Cancer</source>
<year>2015</year>; <volume>15</volume>: <fpage>667</fpage>.<pub-id pub-id-type="pmid">26452347</pub-id></mixed-citation></ref><ref id="cas13232-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cas13232-cit-0015">
<string-name>
<surname>Miyake</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Miyazaki</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Imai</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Harada</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fujisawa</surname>
<given-names>M</given-names>
</string-name>. <article-title>Early tumor shrinkage under treatment with first&#x02010;line tyrosine kinase inhibitors as a predictor of overall survival in patients with metastatic renal cell carcinoma: a retrospective multi&#x02010;institutional study in Japan</article-title>. <source>Target Oncol</source>
<year>2016</year>; <volume>11</volume>: <fpage>175</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">26341668</pub-id></mixed-citation></ref><ref id="cas13232-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cas13232-cit-0016">
<string-name>
<surname>Motzer</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Bacik</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Russo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mazumdar</surname>
<given-names>M</given-names>
</string-name>. <article-title>Interferon&#x02010;alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma</article-title>. <source>J Clin Oncol</source>
<year>2002</year>; <volume>20</volume>: <fpage>289</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">11773181</pub-id></mixed-citation></ref><ref id="cas13232-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cas13232-cit-0017">
<string-name>
<surname>Heng</surname>
<given-names>DY</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Regan</surname>
<given-names>MM</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor&#x02010;targeted agents: results from a large, multicenter study</article-title>. <source>J Clin Oncol</source>
<year>2009</year>; <volume>27</volume>: <fpage>5794</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19826129</pub-id></mixed-citation></ref></ref-list></back></article>